In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements OT-101 which continues to demonstrate potent activity against SARS-CoV-2 and expands the company’s
OT-101 - a TGF- β 2 antisense - has demonstrated potent antiviral activity against COVID-19 OT-101 is part of the Company’s proprietary platform for rapid antiviral response to COVID-19 and future viral epidemics AGOURA HILLS, Calif. , April 06, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
AGOURA HILLS, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD PhD, Sanjive Qazi PhD, and Vuong Trieu , PhD in the oncology journal Cancer Reports and Reviews.
OT-101 and two additional candidates demonstrated viral inhibition activity against coronavirus AGOURA HILLS, Calif. , March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an
AGOURA HILLS, Calif. and DEERFIELD, Ill. , March 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI) enabled EdgePoint projects by expanding their partnership with Meridian IT, a leading technology
OT-101- a TGF- β 2 inhibitor - has demonstrated potent antiviral activity against coronavirus OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral response AGOURA HILLS, Calif. , March 18, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
Company has formed a new Division, led by Dr. Cyril Empig , to develop a multi-modal approach to treating the COVID-19 and future emergent zoonotic outbreaks Rapid response platform based on the Company’s proprietary small molecule, antisense, antibody and artificial intelligence (AI) technologies
AGOURA HILLS, Calif. , Dec. 27, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD, the Chief Medical Officer for Mateon, Vuong Trieu , PhD, the Chief Executive Officer and President
AGOURA HILLS, Calif. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), dedicated to the development of innovative treatments for cancer, today announced that the multi-institutional OXI1222 study in people with previously treated relapsed acute myeloid leukemia (AML) met
TrustPoint has the potential to improve documentation processes by automating data documentation and verification leading to improved data integrity and reduced operating expenses Collaboration represents important step for commercialization of proprietary AI/blockchain vision technology by Mateon
